S3 guideline „actinic keratosis and cutaneous squamous cell carcinoma“ – update 2023, part 2: epidemiology and etiology, diagnostics, surgical and systemic treatment of cutaneous squamous cell carcinoma (cSCC), surveillance and prevention
Autor(en): | Leiter, Ulrike Heppt, Markus V. Steeb, Theresa Alter, Mareike Amaral, Teresa Bauer, Andrea Bechara, Falk G. Becker, Jürgen C. Breitbart, Eckhard W. Breuninger, Helmut Diepgen, Thomas Dirschka, Thomas Eigentler, Thomas ElGammal, A. K. Stephan Felcht, Moritz Flaig, Michael J. Follmann, Markus Fritz, Klaus Grabbe, Stephan Greinert, Rüdiger Gutzmer, Ralf Hauschild, Axel Hillen, Uwe Ihrler, Stephan John, Swen Malte Kofler, Lukas Koelbl, Oliver Krause-Bergmann, Albrecht Kraywinkel, Klaus Krohn, Steffen Langer, Thomas Loquai, Carmen Löser, Christoph R. Mohr, Peter Nashan, Dorothée Nothacker, Monika Pfannenberg, Christina Salavastru, Carmen Schmitz, Lutz Stockfleth, Eggert Szeimies, Rolf-Markus Ulrich, Claas Voelter-Mahlknecht, Susanne Vordermark, Dirk Weichenthal, Michael Welzel, Julia Wermker, Kai Wiegand, Susanne Garbe, Claus Berking, Carola |
Stichwörter: | Aged; Bowen's Disease; Carcinoma, Squamous Cell; Humans; Keratosis, Actinic; Skin; Skin Neoplasms; actinic cheilitis; actinic keratosis; adjuvant radiotherapy; advanced cancer; Article; Bowen disease; cancer classification; cancer diagnosis; cancer epidemiology; cancer palliative therapy; cancer prevention; cancer prognosis; cancer recurrence; cancer staging; cancer surgery; consensus; disease surveillance; evidence based practice; field cancerization; follow up; head and neck surgery; high risk population; histopathology; human; immune deficiency; lymph node dissection; metastasis; nomenclature; non invasive measurement; non invasive procedure; occupational disease; oncogenesis and malignant transformation; phase 1 clinical trial (topic); phase 2 clinical trial (topic); postoperative care; postoperative radiotherapy; practice guideline; primary prevention; primary tumor; prophylactic lymphadenectomy; prophylactic surgical procedure; risk factor; squamous cell skin carcinoma; systemic therapy; vulnerable population; actinic keratosis; aged; Bowen disease; pathology; skin; skin tumor; squamous cell carcinoma | Erscheinungsdatum: | 2023 | Herausgeber: | John Wiley and Sons Inc | Journal: | JDDG - Journal of the German Society of Dermatology | Volumen: | 21 | Ausgabe: | 11 | Startseite: | 1422 – 1433 | Zusammenfassung: | Actinic keratosis (AK) are common lesions in light-skinned individuals that can potentially progress to cutaneous squamous cell carcinoma (cSCC). Both conditions may be associated with significant morbidity and constitute a major disease burden, especially among the elderly. To establish an evidence-based framework for clinical decision making, the guideline “actinic keratosis and cutaneous squamous cell carcinoma” was updated and expanded by the topics cutaneous squamous cell carcinoma in situ (Bowen's disease) and actinic cheilitis. The guideline is aimed at dermatologists, general practitioners, ear nose and throat specialists, surgeons, oncologists, radiologists and radiation oncologists in hospitals and office-based settings, as well as other medical specialties, policy makers and insurance funds involved in the diagnosis and treatment of patients with AK and cSCC. A separate guideline exists for patients and their relatives. In this part, we will address aspects relating to epidemiology and etiology, diagnostics, surgical and systemic treatment of cutaneous squamous cell carcinoma (cSCC), surveillance and prevention. © 2023 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by Wiley-VCH GmbH on behalf of Deutsche Dermatologische Gesellschaft. |
Beschreibung: | Cited by: 0; All Open Access, Hybrid Gold Open Access |
ISSN: | 1610-0379 | DOI: | 10.1111/ddg.15256 | Externe URL: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85174195158&doi=10.1111%2fddg.15256&partnerID=40&md5=b8130c9bb795f87ca949e3596b3a04d6 |
Zur Langanzeige
Seitenaufrufe
1
Letzte Woche
0
0
Letzter Monat
0
0
geprüft am 02.05.2024